FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Endo USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Endo USA, Inc. to market Fluphenazine Decanoate, a long-acting injectable antipsychotic for schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Fluphenazine decanoate (Fluphenazine decanoate)

Snippet

SUPPL AP for FLUPHENAZINE DECANOATE (FLUPHENAZINE DECANOATE)